Speaker
Hemmie Chang
PARTNER & CO-CHAIR, LIFE SCIENCES GROUP; CHAIR, LICENSING & STRATEGIC ALLIANCES, FOLEY HOAG LLP
As Chair of Foley Hoag's Licensing & Strategic Alliances Practice, Hemmie Chang regularly advises clients on high profile intellectual property transactions. Her career-spanning dedication to clients and significant influence on the life sciences industry earned her an induction into the LMG Life Sciences Hall of Fame in 2019, as well as recognition as a USA Top Women Dealmaker Awards, hosted by the Global M&A Network in 2022.
Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the biopharmaceutical, medical device, diagnostics, gene and cell therapy and genomics sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals - all of which involve a broad range of intellectual property assets, from patents and trade secrets to trademarks and copyrights. Hemmie has closed more than $20 billion in deals across diverse therapeutic areas opposite major pharma and biotech partners such as AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen Biotech, Merck, Novartis, Novo Nordisk and Takeda.
Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the biopharmaceutical, medical device, diagnostics, gene and cell therapy and genomics sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals - all of which involve a broad range of intellectual property assets, from patents and trade secrets to trademarks and copyrights. Hemmie has closed more than $20 billion in deals across diverse therapeutic areas opposite major pharma and biotech partners such as AbbVie, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen Biotech, Merck, Novartis, Novo Nordisk and Takeda.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
